Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT

Environmental and Molecular Mutagenesis

Volumn 48, Issue 3-4, 2007, Pages 299-306

  Hong, Hue Hua L ^a   Dunnick, June ^a   Herbert, Ronald ^a   Devereux, Theodora R ^a   Kim, Yongbaek ^a   Sills, Robert C ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

3 azido 3 deoxythymidine; AZT; K ras oncogene; Lung cancer; p53 tumor suppressor gene; Swiss mice; Transplacental carcinogenesis

Indexed keywords

ADENINE; DNA; GUANINE; THYMIDINE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENETICS; CARCINOGEN DNA INTERACTION; CODON; CONTROLLED STUDY; DOSE RESPONSE; EXON; FEMALE; GENE SEQUENCE; GENOMIC INSTABILITY; LUNG CARCINOGENESIS; LUNG TUMOR; MALE; MOUSE; MUTATIONAL ANALYSIS; NEWBORN; NONHUMAN; ONCOGENE K RAS; OXIDATIVE STRESS; PERINATAL DRUG EXPOSURE; POINT MUTATION; POLYMERASE CHAIN REACTION; SWISS WEBSTER MOUSE; TRANSPLACENTAL CARCINOGENESIS; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTI-HIV AGENTS; FEMALE; GENES, P53; GENES, RAS; LUNG NEOPLASMS; MATERNAL-FETAL EXCHANGE; MICE; MICE, INBRED STRAINS; MUTATION; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53; ZIDOVUDINE;

MUS;

EID: 34047208268     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20197     Document Type: Article

References (51)

1. Belinsky SA, Devereux TR, Foley JF, Maronpot RR, Anderson MW. 1992. Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse. Cancer Res 52:3164-3173.
2. Bialkowska A, Bialkowski K, Gerschenson M, Diwan BA, Jones AB, Olivero OA, Poirier MC, Anderson LM, Kasprzak KS, Sipowicz MA. 2000. Oxidative DNA damage in fetal tissues after transplacental exposure to 3′-azido- 3′-deoxythymidine (AZT). Carcinogenesis 21:1059-1062.
3. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy J, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331:1173-1180.
4. Devereux TR, Holliday W, Anna C, Ress N, Roycroft J, Sills RC. 2002. Map kinase activation correlates with K-ras mutation and loss of heterozygosity on chromosome 6 in alveolar bronchiolar carcinomas from B6C3F1 mice exposed to vanadium pentoxide for 2 years. Carcinogenesis 23:1737-1743.
5. Diwan BA, Riggs CW, Logsdon D, Haines DC. Olivero OA, Rice JM, Yuspa SH, Poirier MC, Anderson LM. 1999. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′deoxythymidine in mice. Toxicol Appl Pharmacol 161:82-99.
6. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
7. Harris CC. 1993. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980-1981.
8. Harris CC. 1996. p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 17:1187-1198.
9. Hegi ME, Soderkvist P, Foley JF, Schoonhoven R, Swenberg JA, Kari F, Maronpot R, Anderson MW, Wiseman RW. 1993. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis 14:803-810.
10. Hegi ME, Devereux TR, Dietrich WF, Cochran CJ, Lander ES, Foley JF, Maronpot RR, Anderson MW, Wiseman RW. 1994. Allelo-type analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Res 54:6257-6264.
11. Henderson PT, Delaney JC, Gu F, Tannenbaum SR, Essigmann JM. 2002. Oxidation of 7,8-dihydro-8-oxoguanine affords lesions that are potent sources of replication errors in vivo. Biochemistry 41:914-921.
12. Hong HL, Devereux TR, Melnick RL, Moomaw CR, Boorman GA, Sills RC. 2000. Mutations of ras protooncogenes and p53 tumor suppressor gene in cardiac hemangiosarcomas from B6C3F1 mice exposed to 1,3-butadiene for 2 years. Toxicol Pathol 28:529-534.
13. Hong HL, Ton TV, Devereux TR, Moomaw C, Clayton N, Chan P, Dunnick JK, Sills RC. 2003. Chemical-specific alterations in ras, p53, and β-catenin genes in hemangiosarcomas from B6C3F1 mice exposed to o-nitrotoluene or riddelliine for 2 years. Toxicol Appl Pharmacol 191:227-234.
14. Janssen YMW, Van Houten B, Borm PJA, Mossman BT. 1993. Cell and tissue responses to oxidative damage. Lab Invest 69:261-274.
15. Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Taniere P, Brennan P, Boffetta P, Zaridze DG, Hainaut P. 2005. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 65:5076-5083.
16. Leone-Kabler S, Wessner LL, McEntee MF, D'Agostino RB Jr, Miller MS. 1997. Ki-ras mutations are an early event and correlate with tumor stage in transplacentally-induced murine lung tumors. Carcinogenesis 18:1163-1168.
17. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
18. Lewis W, Copeland WC, Day BJ. 2001. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest 81:777-790.
19. Lewis W, Day BJ, Copeland WC. 2003. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2:812-822.
20. Maronpot RR, Fox T, Malarkey D, Goldsworthy T. 1995. Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 101:125-156.
21. McKenna IM, Ramakrishna G, Diwan BA, Shiao Y, Kasprzak KS, Powell DA, Anderson LM. 2001. K-ras mutations in mouse lung tumors of extreme age: independent of paternal preconceptional exposure to chromium(III) but significantly more frequent in carcinomas than adenomas. Mutat Res 490:57-65.
22. Meng Q, Walker DM, Olivero OA, Xiaochu S, Antiochos BB, Poirier MC, Walker VE. 2000. Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci USA 97:12667-12671.
23. Meng Q, Su T, O'Neill JP, Walker VE. 2002. Molecular analysis of mutations at the HPRT and TK Loci of human lymphoblastoid cells after combined treatments with 3′-azido-3′deoxythymidine and 2′,3′- dideoxyinosine. Environ Mol Mutagen 39:282-295.
24. Miller MS, Leone-Kabler S, Rollins LA, Wessner LL, Fan M, Schaeffer DO, McEntee MF, O'Sullivan MG. 1998. Molecular pathogenesis of transplacentally induced mouse lung tumors. Exp Lung Res 24:557-577.
25. National Toxicology Program. 1999. Reproductive, developmental, and general toxicity study of 3′-azido-3′-deoxythymidine (AZT) and isoniazid combinations administered by gavage to Swiss (CD-1) mice. Research Triangle Park, NC: National Institute of Environmental Health Sciences. NIH Publication No. 99-3941.
26. National Toxicology Program. 2004. Toxicology and carcinogenesis studies of transplacental AZT in Swiss (CD-1) mice (in utero studies). Research Triangle Park, NC: National Institute of Environmental Health Sciences. NIH Publication No. 04-4458.
27. Oleson FB, Getman SM. 1990. Multiple-dose erythrocyte micronucleus assays in mice and rats with azidothymidine (AZT). Environ Mol Mutagen 15 (Suppl 17):46.
28. Olivero OA, Anderson LM, Diwan BA, Mines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC. 1997. Transplacental effects of 3′-azido-3′deoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 89:1602-1608.
29. Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Landay AL, Baker R, Stek AM, Khoury MM, Proia LA, Kessler HA, Sha BE, Tarone RE, Poirier MC. 1999. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS 13:919-25.
30. Olivero OA, Reddy MK, Pietras SM, Poirier MC. 2001. Plasma drug levels compared with DNA incorporation of 3′-azido-3′deoxythymidine (AZT) in adult cynomolgus (Macaco fascicularis) monkeys. Exp Biol Med 226:446-449.
31. Olivero OA, Fernandez JJ, Antiochos BB, Wagner JL, St. Claire ME, Poirier MC. 2002. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr 29:323-329.
32. Osada H, Takahashi T. 2002. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 21:7421-7434.
33. Phillips MD, Nascimbeni B, Tice RR, Shelby MD. 1991. Induction of micronuclei in mouse bone marrow cells: an evaluation of nucleoside analogues used in the treatment of AIDS. Environ Mol Mutagen 18:168-183.
34. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, Landay AL, Walker VE, Charurat M, Blattner WA. 2003. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 33:175-183.
35. Rodenhuis S, Slebos RJC. 1992. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52:2665S-2669S.
36. Rodin SN, Rodin AS. 2005. Origins and selection of p53 mutations in lung carcinogenesis. Semin Cancer Biol 15:103-112.
37. Shafik HM, Nokta MA, Pollard RB. 1991. Recombinant human interferon β ser protects against zidovudine-induced genetic damage in AIDS patients. Antiviral Res 16:205-212.
38. Shigenaga MK, Ames BN. 1991. Assays for 8-hydroxy-2′- deoxyguanosine: a biomarker of in vivo oxidative DNA damage. Free Radic Biol Med 10:211-216.
39. Sills RC, Hong HL, Greenwell A, Herbert RA, Boorman GA, Devereux TR. 1995. Increased frequency of K-ras mutations in lung neoplasms from female B6C3F1 mice exposed to ozone for 24 or 30 months. Carcinogenesis 16:1623-1628.
40. Sills RC, Boorman GA, Neal JE, Hong HL, Devereux TR. 1999a. Mutations in ras genes in experimental tumours of rodents. In: McGregor DB, Rice JM, Venitt S, editors. The Use of Short- and Medium-Term Tests for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluation. Lyon, France: IARC. pp 55-86.
41. Sills RC, Hong HL, Melnick RL, Boorman GA, Devereux TR. 1999b. High frequency of codon 61 K-ras A to T transversions in lung and Harderian gland neoplasms of B6C3F1 mice exposed to chloroprene (2-chloro-1,3-butadiene) for 2-years, and comparisons with the structurally related chemicals isoprene and 1,3-butadiene. Carcinogenesis 20:657-662.
42. Sills RC, Hong HL, Flake G, Moomaw C, Clayton N, Boorman GA, Dunnick J, Devereux TR. 2004. o-Nitrotoluene-induced large intestinal tumors in B6C3F1 mice model human colon cancer in their molecular pathogenesis. Carcinogenesis 25:605-612.
43. Steinbrook R. 2004. The AIDS epidemic in 2004. N Engl J Med 351:115-117.
44. Tam AS, Foley JF, Devereux TR, Maronpot RR, Massey TE. 1999. High frequency and heterogenous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors. Cancer Res 59:3634-3640.
45. Tchou J, Kasai H, Shibutani S, Chung MH, Lavai J, Grollamn AP, Nishimura S. 1991. 8-Oxogyanine (8-hydroxyguanine) DNA glycosylase and its substrate specificity. Proc Natl Acad Sci USA 88:4690-4694.
46. Trukhanova LS, Hong HL, Sills RC, Bowser AD, Gaul B, Boorman GA, Turusov VS, Devereux TR, Dixon D. 1998. Predominant p53 G to A transition mutation and enhanced cell proliferation in uterine sarcomas of CBA mice treated with 1,2-dimethylhydrazine. Toxicol Pathol 26:367-374.
47. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10:789-799.
48. Von Tungeln LS, Hamilton LP, Dobrovolsky VN, Bishop ME, Shaddock JG, Heflich RH, Beland FA. 2002. Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in B6C3F1/Tk +/- mice treated neonatally with zidovudine and lamivudine. Carcinogenesis 23:1427-1432.
49. Wessner LL, Fan M, Schaeffer DO, McEntee MF, Miller MS. 1996. Mouse lung tumors exhibit specific Ki-Ras mutations following transplacental exposure to 3-methylcholanthrene. Carcinogenesis 17:1519-1526.
50. Witt KL, Tice RR, Wolfe GW, Bishop JB. 2004. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3′-azido-3′-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment. Environ Mol Mutagen 44:321-328.
51. Zhang Z, Diwan BA, Anderson LM, Logsdon D, Olivero OA, Haines DC, Rice JM, Yuspa SH, Poirier MC. 1998. Skin tumorigenesis and Ki-ras and Ha-ras mutations in tumors from adult mice exposed in utero to 3′-azido-2′, 3′-dideoxythymidine. Mol Carcinog 23:45-51.